Morphological changes in erythrocytes during disease, aging, or reactions to external agents are significant as they can influence disease progression. However, the exact mechanisms behind these temporary alterations and their potential to cause dysfunction remain unclear. Using a saponin-induced erythrocyte shape transition (EST) model, we studied the gradual shift of erythrocytes towards echino-stomato-spherocytic forms and its link to hemolysis and thrombosis. We observed that different saponin concentrations elicited varying shape transformations. At low concentrations, erythrocytes transition from discocytic shapes to echinocytic, echino-stomatocytic, and ultimately stomatocytic forms. As the concentration moderately increases, the morphology evolves into stomato-spherocytic forms. At higher saponin concentrations, the erythrocytes completely transform into spherocytic forms. Regardless of the transformation degree, all forms showed increased phosphatidylserine exposure (PS) and microvesicle (MV) production, primarily due to increased scramblase and decreased flippase activity, which were influenced by elevated calcium levels and caspase 3 activity, effectively managing PS distribution and influencing cell membrane expansion and invagination. These alterations increased thrombin production, erythrocyte adhesion, and aggregation, promoting thrombosis in rats. Altogether, our findings indicate that the shift towards echino-stomato-spherocytic forms fosters a hypercoagulable state through PS externalization, heightening thrombotic risk.
Collagen plays a crucial role in platelet activation and thrombosis, yet the underlying mechanisms involving reactive oxygen species (ROS) remain incompletely understood. This study investigated how collagen modulates ROS generation and platelet aggregation both in vitro and in vivo, as well as evaluating the protective effects of antioxidants. In vitro, collagen induced dose-dependent platelet aggregation and increased ROS generation, evidenced by the enhanced EMPO adduct formation detected via electron spin resonance (ESR). In vivo experiments demonstrated that collagen administration significantly accelerated CAT-1 decay, indicating elevated oxidative stress with a transient peak around 1 minute post-treatment. Furthermore, escalating collagen doses correlated with increased ROS generation and reduced survival rates in mice, underscoring collagen’s impact on oxidative stress and thrombosis severity. Importantly, treatment with enzymatic antioxidants (superoxide dismutase, catalase) and non-enzymatic antioxidants (DMTU, Tiron, mannitol) significantly attenuated collagen-induced oxidative stress and improved animal survival. Collectively, these findings elucidate the pivotal role of ROS in collagen-induced platelet activation and thrombosis and highlight antioxidants as promising therapeutic candidates for preventing thrombotic disorders and managing cardiovascular risk.
Enterohemorrhagic Escherichia coli (EHEC) causes thrombotic microangiopathy, yet the red blood cell (RBC)–centered mechanism has remained unclear. We identify the RTX-family hemolysin EhxA as the driver of RBC-mediated thrombogenesis. Deletion of ehxA abolishes Ca 2+ influx, phosphatidylserine (PS) exposure, progression from discocyte to echinocyte to spherocyte, thrombin generation, RBC-endothelium adhesion, and RBC aggregation. Genetic complementation restores these readouts to wild type, and purified EhxA in bacteria-free assays recapitulates them while localizing to intact RBC membranes. By contrast, Δ stx2 mutants do not elicit these RBC phenotypes, distinguishing this pathway from Shiga toxin–dependent effects. Multiple regression quantifies the link between PS exposure, morphology, and procoagulant outputs. In rats, infection with wild type increased RBC remodeling and venous thrombosis, whereas infection with Δ ehxA did not. Together, the data define an EhxA-Ca 2+ -PS pathway that drives RBC structural remodeling and procoagulant activation during EHEC infection and nominate RTX toxins as targets for preventing toxin-induced coagulopathies.
Adenoviral vector vaccines were pivotal for COVID-19 control, but postmarketing safety surveillance has identified venous-predominant thrombotic risks not fully explained by platelet-centric mechanisms. We tested an RBC-associated hypothesis using an Ad5 vector-rAd/HA(PR8) rat model within a predefined sub-hemolytic window (<10% hemolysis). Ex vivo, we quantified RBC surface phosphatidylserine (PS) exposure, morphology remodeling by scanning electron microscopy, and microvesicle generation, all aligning with increased procoagulant activity. RBCs also exhibited dose-dependent increases in thrombin generation 4 h after intravenous exposure (108–109 OPU/Rat). In vivo, an inferior vena cava thrombosis model showed a pronounced, dose-responsive rise in thrombus burden, consistent with increased thrombogenic potential. Together, these integrated data provide experimental evidence consistent with RBC involvement under adenoviral exposure, supporting a biologically plausible link to the venous-predominant epidemiology observed during the COVID-19 vaccination era. Reported clinical adenoviral vaccine doses are of the same order of magnitude as the exposures tested here, supporting translational relevance while not implying inter-species or product equivalence. Incorporating RBC-focused endpoints, including PS exposure, morphology indices, microvesicle counts, and thrombin generation, into preclinical and early clinical assessments may enhance safety evaluation and inform vector design to mitigate venous thrombotic risk.